Nisa Investment Advisors
EVLO

Nisa Investment Advisors’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Nisa Investment Advisors’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-130
Closed -$9K – 2542
2022
Q1 		$9K Buy
+130
New +$10.8K ﹤0.01% 2235

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nisa Investment Advisors's EVLO Position: Q2 2022 in Review

Nisa Investment Advisors sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2022, closing a stake of 130 shares — an estimated $9K sold.

Nisa Investment Advisors first reported a position in EVLO in Q1 2022 and held it in 1 quarter. The position peaked at $9K in Q1 2022. 46 funds tracked by Wall St. Rank hold EVLO as of Q2 2022.

  • Nisa Investment Advisors reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nisa Investment Advisors sold 130 Evelo Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $9K.
  • Nisa Investment Advisors first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Nisa Investment Advisors's Evelo Biosciences, Inc. Common Stock position peaked at $9K in Q1 2022.
  • 46 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2022.

Based on Nisa Investment Advisors's 13F filing for Q2 2022, filed 3 Aug 2022.